Amgen, the biggest independent biotechnology company in the world, said it bought back $ 10.7 billion worth of stock last quarter — seven times bigger than its 2017 buyback and an 8.5 percent decrease in its total share count.
A biotechnology pioneer since 1980, Amgen has grown to be one of the world's leading independent biotechnology companies, has reached millions of patients around the world and is developing a pipeline of medicines with breakaway potential.